Evidence map›Paper›PMID 30408271›Full record

Trial reportDepression and anxiety2019

A neuromarker of clinical outcome in attention bias modification therapy for social anxiety disorder.

Gal Arad, Rany Abend, Daniel S Pine, Yair Bar-Haim

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Depression and anxiety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Gal AradSchool of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-7229-0516
Rany AbendSection on Development and Affective Neuroscience, National Institute of Mental Health, Bethesda, Maryland.
Daniel S PineSection on Development and Affective Neuroscience, National Institute of Mental Health, Bethesda, Maryland.
Yair Bar-HaimSchool of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel.
National Institutes of Health · USTel Aviv University · IL

Funding

fMRI Studies Of Pediatric Mood And Anxiety DisordersZIAMH002781 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PINE, DANIEL · 2009 to 2025
$41.5M
Fmri Studies Of Risk For Mood And Anxiety Disorders In ChildrenZIAMH002782 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PINE, DANIEL · 2009 to 2025
$28.3M
Intramural NIH HHS ZIA MH002781
6 · The paper itself

Abstract

backgroundAttention bias modification (ABM) therapy aims to modify threat-related attention patterns via computerized tasks. Despite showing medium clinical effect sizes for anxiety disorders, underlying neural-cognitive mechanisms of change remain unclear. We used visual mismatch negativity (vMMN), an event-related potential sensitive to violations of learned statistical contingencies, to assess therapy-related contingency extraction processes in healthy participants and in patients with social anxiety disorder (SAD). We then assessed whether vMMN amplitude predicts ABM treatment outcome.

methodsA modified version of the dot-probe task was used to elicit vMMN, in which 80% of trials were standard and 20% were deviant. In study 1, 30 healthy adults were randomly assigned to one of two ABM conditions: one in which threat-congruent targets were deviant trials and threat-incongruent targets were standard trials, and another in which the contingency was reversed. Electroencephalography (EEG) was continuously measured and vMMN analyzed. In study 2, 38 patients with SAD underwent six sessions of ABM therapy. We tested whether rule extraction in the ABM task, indicated by vMMN amplitude, predicts treatment outcome.

resultsvMMN clearly emerged over prespecified scalp locations indicating contingency extraction during ABM (study 1). vMMN amplitude predicted clinical improvement after ABM therapy, uniquely accounting for 7% and 14.4% of the variance in clinician-rated and self-reported posttreatment SAD symptoms, respectively.

conclusionsvMMN emerges as a neural marker for contingency learning in ABM, suggesting a significant role for contingency extraction processes in the clinical efficacy of this therapy.

Indexed as

Attentional BiasCognitive Behavioral TherapyAdultElectroencephalographyEvoked PotentialsFemaleHumansMalePhobia, SocialSelf ReportTreatment OutcomeYoung Adultanxietyattention biasattention bias modificationelectroencephalographysocial anxiety disordervisual mismatch negativity

Identifiers

PMID30408271
PMCPMC7643035
OpenAlexW2899725370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.